A rapid and scalable method for selecting recombinant mouse monoclonal antibodies by Crosnier, Cécile et al.
Crosnier et al. BMC Biology 2010, 8:76
http://www.biomedcentral.com/1741-7007/8/76
Open Access METHODOLOGY ARTICLE
© 2010 Crosnier et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Methodology article A rapid and scalable method for selecting 
recombinant mouse monoclonal antibodies
Cécile Crosnier, Nicole Staudt and Gavin J Wright*
Abstract
Background: Monoclonal antibodies with high affinity and selectivity that work on wholemount fixed tissues are 
valuable reagents to the cell and developmental biologist, and yet isolating them remains a long and unpredictable 
process. Here we report a rapid and scalable method to select and express recombinant mouse monoclonal antibodies 
that are essentially equivalent to those secreted by parental IgG-isotype hybridomas.
Results: Increased throughput was achieved by immunizing mice with pools of antigens and cloning - from small 
numbers of hybridoma cells - the functionally rearranged light and heavy chains into a single expression plasmid. By 
immunizing with the ectodomains of zebrafish cell surface receptor proteins expressed in mammalian cells and 
screening for formalin-resistant epitopes, we selected antibodies that gave expected staining patterns on wholemount 
fixed zebrafish embryos.
Conclusions: This method can be used to quickly select several high quality monoclonal antibodies from a single 
immunized mouse and facilitates their distribution using plasmids.
Background
The ability of antibodies to bind, with high selectivity and
affinity, to diverse chemical structures has made them an
extremely important tool for biomedical research [1].
Their value is underlined by the numerous ongoing inter-
national efforts, both academic and commercial, to pro-
duce large antibody resources for the scientific
community [2]. A great deal of effort has, therefore, been
applied to both improve antibody selection and develop
other types of affinity binders including the use of other
protein scaffolds [3-5] or nonproteinaceous reagents [6].
Ideally, a binding reagent should have a high affinity
and specificity for its target and be produced quickly with
little resource. However, these two parameters are usually
traded against each other. Monoclonal antibodies raised
in vivo within the mammalian immune system are
matured by somatic hypermutation and, therefore, usu-
ally produce high affinity antibodies, but they are rela-
tively slow to isolate. Conversely, antibodies selected
from in vitro libraries can be produced more rapidly but
are typically of lower binding strength due to the lack of
affinity maturation. Importantly, antibodies that have low
affinities are often unsuitable for applications commonly
used by cell and developmental biologists, such as whole-
mount immunohistochemistry, because of the extensive
washing steps required by these protocols.
Although polyclonal antisera are an efficient and rapid
way of raising high affinity antibodies, they are finite and
can suffer from substantial batch-to-batch variation [7].
By providing essentially limitless amounts of a defined
reagent, monoclonal antibodies selected from an immu-
nized animal therefore remain the reagent of choice.
They are, however , generally regarded as unsuitable for
building large resources because of the requirement for
long immunization schedules and a large tissue culture
demand. Despite efforts to alleviate some aspects of this
procedure, the large tissue culture burden of subsequent
hybridoma cell cloning remains a significant barrier for
large scale production [8,9]. Also, the use of chemically
synthesized peptides as antigens is rapid and cost effec-
tive but, in many cases, these reagents do not adequately
mimic the shape of a natively folded protein. Antibodies
raised against peptides, therefore, often recognize only
denatured proteins (for example on western blots) and do
not stain native proteins found in wholemount fixed tis-
sue, thus limiting their usefulness.
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The zebrafish is an increasingly popular model organ-
ism used to understand early vertebrate developmental
processes and model diseases [10-12]. The amenability to
forward genetics and the ability to produce large numbers
of translucent embryos that rapidly develop externally
has enabled the genetic dissection of most vertebrate
organ systems [13,14]. While significant advances have
been made in genetic methods [15,16], the paucity of high
quality antibodies is considered a significant limitation
for zebrafish research [17]. The few antibody reagents
available to zebrafish researchers have mostly come from
'shotgun' approaches where zebrafish tissue lysates were
used as immunogens [9,18,19]. While this approach is
valuable, the target antigen is not immediately known and
the isolated antibodies frequently recognize highly
immunogenic fish-specific glycans, which may not be
protein specific [18,20].
In order to identify novel signalling pathways initiated
by extracellular protein interactions between cell surface
and secreted receptor-ligand pairs, we have recently com-
piled a library containing the ectodomain fragments of
249 zebrafish glycoproteins which mainly belong to the
immunoglobulin (IgSF) and leucine-rich repeat (LRR)
families [21,22]. This protein library represents a useful
source of antigens to raise antibodies that can be used not
only as differentiation markers but also to isolate intact
living cells from suspensions, or ectopically activate sig-
nalling pathways. Furthermore, expressing these entire
ectodomains in mammalian cells ensures that structurally
important posttranslational modifications, such as glyco-
sylation and disulfide bonds, are added and the proteins
are therefore more likely to be natively folded.
Here, we report the development and implementation
of a convenient and scalable method for selecting mouse
monoclonal antibodies against several zebrafish cell sur-
face receptor proteins in parallel. We have developed a
procedure for the rapid cloning of both the functionally
rearranged heavy and light chains into a single expression
plasmid from a small number of hybridoma cells. By
screening for formalin-resistant epitopes we show that
this procedure produces antibodies that display the
expected staining on wholemount fixed tissues. The use
of a single antibody expression plasmid facilitates the dis-
tribution of these reagents making it suitable for compil-
ing an antibody resource.
Methods
Protein production and purification
All zebrafish receptor ectodomain fragments were pro-
duced in HEK293E cells as rat Cd4 domains three- and
four-tagged secreted proteins. The Cd4 tag was followed
by either a six histidine-tag for purification or an enzy-
matic biotinylation site and cotransfected with the BirA
enzyme, essentially as described [21]. Supernatants were
harvested 6 days after transfection, filtered and stored at
4°C. Histidine-tagged proteins were purified with His-
Trap HP columns (GE Healthcare, Buckinghamshire, UK)
as previously described [21]. Proteins were over 90% pure
as determined by SDS-PAGE and quantified by measur-
ing absorbance at 280 nm. Antibodies were isotyped
using the ISO-2 isotyping kit (Sigma, MO, USA).
Immunizations
Six-week-old male BALB/c mice were immunized subcu-
taneously with pools of five purified His-tagged proteins
(5 μg each protein per immunization) in complete Fre-
und's adjuvant (once) and incomplete adjuvant (three
times). Mice selected for hybridoma production were
boosted intraperitoneally 3 days before dissecting the
spleen.
Cell culture and hybridoma generation
The SP2/0 myeloma and SP2/mIL6 cell lines were grown
in advanced DMEM/F12 medium (Invitrogen, CA, USA)
supplemented with 20% fetal bovine serum, penicillin
(100 U/mL), streptomycin (100 μg/mL) and L-glutamine
(2 mM). SP2/mIL6 conditioned medium was harvested
every 3 days. Following spleen dissection and dissocia-
tion, 108 splenocytes were fused to 107 SP2/0 myeloma in
50% PEG (PEG 1500, Roche, Hertfordshire, UK), using
standard procedures. The resulting hybridomas were
plated over 10 96-well plates and initially grown in
advanced DMEM/F12 medium (Invitrogen) supple-
mented with 20% fetal bovine serum, 20% Sp2/mIL6 con-
ditioned medium, penicillin (100 U/mL), streptomycin
(100 μg/mL) and L-glutamine (2 mM) before addition of
hypoxanthine aminopterin thymidine (HAT) selection
medium 24 h after the fusion; after a regular exchange of
selection medium for 2 weeks, hybridoma supernatants
w e r e  h a r v e s t e d  f o r  s c r e e n i n g .  P o s i t i v e  c l o n e s  w e r e  r e -
plated and grown for a further 5 days.
Antibody screening
Hybridoma supernatants were screened using an ELISA-
based assay. Briefly, the biotinylated ectodomains of the
injected proteins were bound to streptavidin-coated
plates (NUNC, NY, USA) and incubated for 1 h with 50
μL hybridoma supernatant diluted 1:2 in phosphate buff-
ered saline (PBS) and 0.2% bovine serum albumin (BSA).
The plates were washed in PBS/0.1% Tween20 (PBST)
before incubation with an anti-mouse immunoglobulin
antibody coupled to alkaline phosphatase (Sigma) for 1 h
at room temperature. After washes in PBST and PBS,Crosnier et al. BMC Biology 2010, 8:76
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Table 1: Primers used for the generation of recombinant mouse 
monoclonal antibodies.
Primers used for the generation of a leader sequence for the κ light chains
1 GCCACCATGGAGTTTCAGACCCAGGTACTCATGTCCCTGCTGCTCTGCATGT
CTGGTGC
2 GGCCGCACCAGACATGCAGAGCAGCAGGGACATGAGTACCTGGGTCTGAA
ACTCCATGGTGGC
Degenerate forward primers used for the amplification of rearranged κ 
light chains
3 TCAATAGTTGAACATAGCGGCCGCASAAAWTGTKCTCACCCAGTC
4 TCAATAGTTGAACATAGCGGCCGCAGAWATTGTGCTMACTCAGTC
5 TCAATAGTTGAACATAGCGGCCGCAGACATTGTGCTRACACAGTC
6 TCAATAGTTGAACATAGCGGCCGCAGACATTGTGATGACMCAGTC
7 TCAATAGTTGAACATAGCGGCCGCAGAYATCMAGATRAMCCAGTC
8 TCAATAGTTGAACATAGCGGCCGCAGAYATCCAGATGAYTCAGTC
9 TCAATAGTTGAACATAGCGGCCGCAGATATCCAGATGACACAGAC
10 TCAATAGTTGAACATAGCGGCCGCAGACATTGTGCTGACCCAATC
11 TCAATAGTTGAACATAGCGGCCGCAGACATYSTRATGACCCARTC
12 TCAATAGTTGAACATAGCGGCCGCAGATRTTKTGATGACYCARAC
13 TCAATAGTTGAACATAGCGGCCGCAGAYATTGTGATGACBCAGKC
14 TCAATAGTTGAACATAGCGGCCGCAGATATTGTGATAACCCAGGA
15 TCAATAGTTGAACATAGCGGCCGCAGACATCYTGCTGACYCAGTC
16 TCAATAGTTGAACATAGCGGCCGCAGAAAWTGTGYTGACCCAGTC
17 TCAATAGTTGAACATAGCGGCCGCAGAAACAACTGTGACCCAGTC
18 TCAATAGTTGAACATAGCGGCCGCAGACATTRTGATGWCACAGTC
19 TCAATAGTTGAACATAGCGGCCGCAGACATCCAGMTGACMCARTC
Reverse primer used for the amplification of rearranged κ light chains
20 GGATACAGTTGGTGCAGCATCAGCCC
Primers used for the generation of the joining fragment
21 GGGCTGATGCTGCACCAACTGTA
22 TCAAGTGCAAAGACTCACTTTATTG
23 CAATAAAGTGAGTCTTTGCACTTGATAGTTATTAATAGTAATCAATTACG
24 TAGCAGAACAGGCAGCTTCATGGTGGCCTGGGAGTGGACACCTGTGG
AGAG
25 ATGAAGCTGCCTGTTCTGCTAGTG
26 ACTGCTTGAGGCTGGACTCGTGAACAATAGCAGC
Degenerate forward primers used for the amplification of rearranged 
heavy chains
27 TTCACGAGTCCAGCCTCAAGCAGTGAKRTRCAGCTTMAGGAGTC
28 TTCACGAGTCCAGCCTCAAGCAGTGAGKTYCAGCTBCAGCAGTC
29 TTCACGAGTCCAGCCTCAAGCAGTCAGGTGCAGMTGAAGSAGTC
30 TTCACGAGTCCAGCCTCAAGCAGTGAGRTCCAGCTGCAACARTC
31 TTCACGAGTCCAGCCTCAAGCAGTCAGGTYVAGCTGCAGCAGTC
32 TTCACGAGTCCAGCCTCAAGCAGTCAGGTYCARCTGCAGCAGTC
33 TTCACGAGTCCAGCCTCAAGCAGTGAGGTGMAGCTGGTGGAATC
34 TTCACGAGTCCAGCCTCAAGCAGTGAVGTGMWGCTSGTGGAGTC
35 TTCACGAGTCCAGCCTCAAGCAGTGARGTGCAGCTGKTGGAGWC
36 TTCACGAGTCCAGCCTCAAGCAGTGAGGTGAAGCTGATGGAATC
37 TTCACGAGTCCAGCCTCAAGCAGTGAGGTGCAGCTTGTTGAGTC
38 TTCACGAGTCCAGCCTCAAGCAGTGAGGTGAAGCTTCTCRAGTC
39 TTCACGAGTCCAGCCTCAAGCAGTGAAGTGAARMTTGAGGAGTC
40 TTCACGAGTCCAGCCTCAAGCAGTCAGGTTACTCWGAAAGWGTCTG
41 TTCACGAGTCCAGCCTCAAGCAGTCAGGTCCAACTGCAGCAGCC
42 TTCACGAGTCCAGCCTCAAGCAGTGATGTGAACCTGGAAGTGTC
43 TTCACGAGTCCAGCCTCAAGCAGTCAGATCCAGTTSGTRCAGTC
44 TTCACGAGTCCAGCCTCAAGCAGTGAGGTRCAGCTKGTAGAGAC
Reverse primers used for the amplification of rearranged heavy chains
45 CTATTCTAGCTAATCTAGGCGCGCCGAGGAGACGGTGACCGTGGTCC
46 CTATTCTAGCTAATCTAGGCGCGCCGAGGAGACTGTGAGAGTGGTGC
47 CTATTCTAGCTAATCTAGGCGCGCCGCAGAGACAGTGACCAGAGTCC
48 CTATTCTAGCTAATCTAGGCGCGCCGAGGAGACGGTGACTGAGGTTC
Primers used for the amplification of the IgG1 constant region
49 ATATCACGGCGCGCCCGACACCCCCATCTGTCTATCCA
50 GACTGATCTAGATCATTTACCAGGAGAGTGGGAGAG
Primers used for fusion polymerase chain reaction
51 TCAATAGTTGAACATAGCGGCCGC
52 CTATTCTAGCTAATCTAGGCGCGCCG
Primer specific for the aberrant κ light chain from SP2/0 myeloma
53 GGATGCTGCAACCTATTACTGTCAGCACATTAGGGAGCTTACACG
The primers used to amplify the rearranged heavy and kappa light variable 
regions were designed using recent genome sequence of the mouse 
immunoglobulin regions: NG_005612 for the κ light locus and NG_005838 for 
the heavy locus. Degenerate base code: M = A+C; R = A+G; W = A+T; S = C+G; Y 
= C+T; K = G+T; V = A+C+G; B = C+G+T.
Table 1: Primers used for the generation of recombinant mouse 
monoclonal antibodies. (Continued)
positive wells were detected with p-nitrophenyl phos-
phate at 1 mg/mL. In order to test for fixation-sensitivity,
protein ectodomains were incubated between 1 min and
2 h in 4% formalin before the addition of the hybridoma
supernatant.
Plasmid construction
The immunoglobulin expression vector was constructed
from a derivative of pTT3 [23] that contains an expanded
multiple cloning site. The leader sequence of the mouse
variable κ light chain 7-33 was introduced by annealing of
primers 1 and 2 (Table 1) and cloning between the PmeI
and NotI restriction sites for production of the recombi-
nant antibody light chain. The constant region of the
mouse immunoglobulin G1 (IgG1) isotype was amplified
from mouse genomic DNA using primers 49 and 50, and
inserted between the AscI and XbaI restriction sites for
expression of the recombinant heavy chain.
RNA preparation and reverse transcriptase polymerase 
chain reaction (RT-PCR)
Total RNAs were prepared from selected hybridoma
using the RNAqueous micro kit (Ambion, Texas, USA)
and the reverse transcription performed with a polydT
primer, using SuperscriptIII (Invitrogen). The function-
ally rearranged light variable region of a selected hybri-
doma was amplified without its signal peptide sequence
using a set of 17 degenerate forward primers containing a
NotI site (primers 3 to 19) and one unique reverse primer
corresponding to the constant region of the κ light chainCrosnier et al. BMC Biology 2010, 8:76
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(primer 20). Similarly, the functionally rearranged heavy
variable region was amplified without its signal peptide
sequence using a set of 18 degenerate forward primers
(primers 27 to 44) and four reverse primers containing an
AscI site (primers 45 to 48). Both heavy and light variable
regions were amplified using Advantage2 polymerase
(Clontech, CA, USA) using the PCR conditions: 94°C for
5 min; five cycles at 94°C for 45 s, 65°C for 30 s, 72°C for 1
min; 19 cycles at 94°C for 45 s, 64.5°C to 55.5°C for 30 s
with 0.5°C decrement per cycle, 72°C for 1 min; and 10
cycles at 94°C for 45 s, 55°C for 30 s, 72°C for 1 min.
Assembly of the expression vector
In order to assemble the light and heavy variable regions,
a joining fragment composed of the constant region of
the κ light chain and its 3' untranslated region, a cyto-
megalovirus (CMV) promoter and the leader sequence of
the mouse variable κ light chain 1-99 was created by
fusion PCR with primers 21 and 26. The κ constant
region and Vκ 1-99 were amplified from mouse genomic
DNA using primers 21 and 22, and 25 and 26, respec-
tively, while the CMV promoter was amplified from the
pTT3 vector with primers 23 and 24. The light and heavy
variable RT-PCR products and the joining fragment were
gel purified and assembled into a contiguous product by
fusion PCR using KOD polymerase (Novagen, Notting-
ham, UK) and primers 51 and 52. PCR conditions were:
94°C for 5 min; five cycles at 94°C for 45 s, 65°C for 30 s,
72°C for 3 min; 19 cycles at 94°C for 45 s, 64.5°C to 55.5°C
for 30 s with 0.5°C decrement per cycle, 72°C for 3 min;
10 cycles at 94°C for 45 s, 55°C for 30 s, 72°C for 3 min.
The fusion PCR product was subsequently cloned into
the immunoglobulin expression vector between the NotI
and AscI restriction sites.
Colony PCR
Plasmids containing a functional variable light and heavy
chain were selected by colony PCR using primers 23, 50
and 53. Primer 53 corresponds to the aberrantly-rear-
ranged light chain present in SP2/0 myeloma and was
used to identify plasmids containing the aberrant SP2/0
light chain with a PCR product size ~2.5 kb. Plasmids
containing both functional light and heavy variable frag-
ments produced a product around 3.1 kb.
Western blotting
Tissue culture medium, transfection medium containing
the recombinant 5F11 antibody or tissue culture medium
spiked with purified 5F11 from the parental hybridoma
were resolved by SDS-PAGE under both reducing and
non-reducing conditions before blotting onto Hybond-P
PVDF membrane (GE Healthcare) overnight at 30 V.
M e m b r a n e s  w e r e  b l o c k e d  w i t h  2 %  B S A  i n  P B S T  a n d
incubated with 1 μg/mL of an anti-mouse IgG-HRP con-
jugate (Molecular Probes, Oregon, USA) diluted in 0.2%
BSA and detected with the Supersignal West pico chemi-
luminescent substrate (Pierce).
Biophysical analysis of antibody affinities
Antibody dissociation rates were determined using a
BIAcore T100 biosensor. Biotinylated Cd4d3 + 4-tagged
recombinant proteins were immobilized onto streptavi-
din-coated SA sensor chip surfaces at low levels (Flrt3
~750 RU, Jamc.2 ~400 RU, Lrrn1 ~1320 RU) and a molar
equivalent of Cd4d3 + 4bio used as a reference. Purified
Unc5bCd4d3 + 4-6H protein was covalently immobilized
(~360 RU) to a CM5 sensor chip using the amine cou-
pling kit (BIAcore, Buckinghamshire, UK). Dissociation
curves were exported and analysed in Microsoft Excel.
Wholemount in situ hybridization and 
immunohistochemistry
Zebrafish were maintained on a 14/10 h light/dark cycle
at 28.5 °C according to the UK Home Office and local
institutional regulations and staged according to Kimmel
[24]. In situ hybridization was performed according to
standard procedures [25] using 100 ng of either unc5b- or
flrt3-RNA probes prepared as described [21]. Bright field
images were captured on an Imager M1 microscope
(Zeiss, Hertfordshire, UK). Purified parental or crude
recombinant 5F11 antibody was diluted 1:500 or 1:2,
respectively, in 10% goat serum, 2% BSA, 0.1% Triton X-
100 in PBS and incubated with cryosections of 3-day-old
formalin-fixed zebrafish embryos. For wholemount stain-
ing, zebrafish embryos were fixed overnight at 4°C in a
4% formalin solution and washed overnight in PBS/1%
Triton X-100. Purified recombinant anti-Unc5b and anti-
Flrt3 antibodies (0.5 mg/mL in PBS) were incubated with
fixed embryos at 4°C overnight followed by three 15 min
wash steps in PBST. For both cryosection and wholem-
ount staining, an anti-mouse-Alexa568 secondary anti-
body was used (1:1000, Invitrogen) and tissues were
counterstained with DAPI. Images of dissected and flat-
mounted embryos were taken on a DM6000B confocal
microscope (Leica, Wetzlar, Germany) and processed
using Adobe Photoshop CS4.
Results
A method for the rapid selection of recombinant mouse 
monoclonal antibodies
Our aim was to rapidly select monoclonal antibodies of
high affinity and specificity that could be used in whole-
mount immunohistochemistry protocols and could be
easily distributed. The successful procedure is outlined in
Figure 1 and is based around standard animal immuniza-
tion and hybridoma technology, which enabled the selec-
tion of antibodies of a given specificity and ensured that
they were affinity matured. Throughput was increased by
immunizing mice with pools of antigens from our libraryCrosnier et al. BMC Biology 2010, 8:76
http://www.biomedcentral.com/1741-7007/8/76
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of zebrafish cell surface and secreted proteins, so that
antibodies to several proteins could be selected simulta-
neously from a single animal. In order to circumvent the
burdensome tissue culture cloning procedures usually
associated with the isolation of hybridomas, the produc-
tively rearranged heavy and light chain loci were ampli-
fied from small numbers of selected hybridoma cells by
RT-PCR. The amplified light and heavy chains were then
joined into a contiguous PCR product and cloned into a
mammalian expression plasmid so that large amounts of
antibody could be quickly produced by transiently trans-
fecting mammalian cells. Recombinant antibodies were
then validated by staining fixed wholemount zebrafish
embryos and the patterns checked for congruence with
the known in situ expression profiles.
Proof-of-principle: cloning of the 5F11 monoclonal 
antibody
In order to clone productively rearranged antibody loci
from hybridomas, we expanded a set of primers to mouse
immunoglobulin V-regions originally published by Kreb-
ber [26] by using more recent genomic sequence infor-
mation (Table 1). This new set of primers can recognize
97 and 98% of functional heavy and kappa (κ) light chain
V-regions, respectively. Lambda light chains only consti-
tute 5% of those used in mouse immunoglobulins [27]
and primers were, therefore, not designed to this light
chain. Hybridomas were generated using the SP2/0
myeloma cell line, which lacks transcription from the
heavy chain locus due to a genomic inversion [28], but is
known to transcribe an aberrantly rearranged κ light
chain [29]. We anticipated that this aberrant light chain
as well as the possible transcription of non-productively
rearranged heavy or light chain loci present in the origi-
nal B-cell could be amplified and would have to be identi-
fied and excluded.
As a proof of principle, we used a hybridoma (5F11)
which secretes a mouse IgG1  recognizing an epitope
restricted to zebrafish basement membranes [18]. Using
our set of primers, we successfully amplified PCR prod-
ucts of expected sizes corresponding to the productively
rearranged variable heavy and light chain regions (Figure
2a). These two products were then assembled by fusion
PCR using a joining fragment that contained (5' to 3') a κ
light chain constant region and its polyadenylation signal,
a CMV promoter and a signal peptide for the heavy chain
(Figure 2b). The primers used for the fusion PCR con-
tained the rare-cutting restriction enzymes NotI and AscI
to facilitate cloning into a single mammalian expression
plasmid, which included a signal peptide for the light
chain and the constant region of the mouse IgG1 antibody
isotype. The final construct contained both light and
heavy chains, each flanked by a CMV promoter and poly-
adenylation sequence (Figure 2c). Although some clones
contained the aberrant SP2/0-derived light chain, we
selected a clone containing both productively rearranged
light and heavy chains.
Western blotting of supernatants from transiently
transfected HEK293E cells under reducing and non-
reducing conditions showed that the heavy and light
chains were stoichiometrically balanced in their expres-
sion level and capable of association (Figure 2d). The
unpurified tissue culture supernatant was used in place of
the primary antibody in an immunohistochemistry pro-
tocol using cryosections of 3-day old zebrafish larvae and
strong staining of the basement membranes was
Figure 1 Overview of a scalable procedure to select recombinant 
mouse monoclonal antibodies. Purified ectodomain fragments of 
zebrafish cell surface and secreted proteins expressed in mammalian 
cells were normalized, pooled and used to immunize mice. Hybrido-
mas were generated by cell fusion, and supernatants screened for pos-
itives using ELISA. The rearranged light and heavy antibody chains 
were amplified from RNA extracted from small numbers of hybridoma 
cells by reverse transcription-polymerase chain reaction and cloned 
into a single expression plasmid. The recombinant monoclonal anti-
bodies were produced by transfecting mammalian cells before testing 
for fixation sensitivity and wholemount staining.Crosnier et al. BMC Biology 2010, 8:76
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observed with the recombinant antibody (Figure 2e)
which was indistinguishable from that obtained with
antibodies secreted by the original hybridoma (Figure 2f).
These data validate the overall strategy for producing
recombinant antibodies from a single expression plasmid.
Multiple different antibodies per fusion using pooled 
antigen immunization
To increase the throughput of monoclonal antibody gen-
eration and show that antibodies could be cloned from
hybridomas at an early stage after selection, we immu-
nized mice with two pools of five different proteins
selected from our library, and performed the fusions
using standard procedures (Table 2). Hybridoma super-
natants were screened by ELISA using the appropriate
biotinylated recombinant proteins immobilized on
streptavidin-coated 96-well plates. Hybridomas secreting
antibodies of interest were expanded for 5 days before
removing ~ 105 cells for total RNA extraction; the super-
natant was retained for antibody isotyping and future
comparisons with recombinant antibodies. For each
hybridoma, cDNA was synthesized and used to indepen-
dently amplify both light and heavy chains before joining
them in a single expression construct. All six hybridomas
for which a heavy chain was cloned contained a produc-
tively rearranged VH region. Only one also had an aber-
rant heavy chain transcript, which presumably originated
from an unproductive rearrangement of the other heavy
chain allele within the fusing B-cell. The only aberrant κ
light chain identified originated from SP2/0 and was
p r e s e n t  i n  2 6 %  t o  7 0 %  o f  p l a s m i d s  d e p e n d i n g  o n  t h e
hybridoma studied; these were quickly identified and
eliminated by colony PCR using a primer specific to this
sequence. In general, cloning of the productively rear-
ranged antibody chains was readily achieved (Table 2). In
two cases (clones 1.2.3 and 1.4.2) cloning was halted due
to the successful completion of a different antibody for
that antigen. In the three other cases where antibody
cloning was not successful, two were due to very small
hybridoma colonies which stopped dividing (clones 1.1.1
and 1.3.1) or because the antibody secretion was lost
(clone 2.4.1).
Single plasmids containing productively rearranged
light and heavy chains were transfected into HEK293E
cells and the supernatant was tested by ELISA to ensure
that the recombinant antibodies retained specificity for
their antigens. After purification from bulk cultures,
yields ranged from 10 μg/mL (SI4-Jamc.2) to 40 μg/mL
(SI3-Flrt3). Of the nine different immunized proteins, 10
positive hybridoma supernatants were identified for
seven antigens and five recombinant antibodies that
retained binding specificity were isolated.
Fixation of biological samples, usually necessary to
maintain tissue architecture for subsequent analysis, can
modify the chemical structure of the protein resulting in
the destruction of antibody epitopes. This is a particular
problem for monoclonal antibodies which recognize a
single epitope. We therefore screened each antibody
against recombinant proteins that had been formalin-
treated for different lengths of time. Of the two antibod-
ies that recognize the Unc5b receptor, one (SI2-Unc5b)
was insensitive and the other (SI1-Unc5b) sensitive to
formalin-treated proteins (Figure 3a). We found, how-
ever, that most epitopes were insensitive to formalin-fixa-
tion (Table 2).
Recombinant and parental hybridoma IgG antibodies have 
comparable affinities
Antibodies cloned and produced recombinantly will dif-
fer in several respects from those secreted by hybrido-
mas. First, all antibodies contain two amino acid changes
(KT to RP) at the junction of the VH and CH1 domains due
to the incorporation of the AscI cloning site. The degen-
Figure 2 Cloning of the 5F11 monoclonal antibody. (a) Reverse 
transcriptase-polymerase chain reaction (PCR) amplification of the 
variable light (VLκ) and heavy (VH) antibody chains from the 5F11 hybri-
doma. (b) Assembly of the 5F11 VLκ and VH regions by fusion PCR 
through a joining fragment resulting in a 2.4 kbp product. (c) Schemat-
ic of the plasmid encoding the recombinant antibody with the fusion 
PCR product cloned between NotI and AscI. (d) Western blot run under 
reducing (left panel) or non-reducing (right panel) conditions: tissue 
culture medium (Med), supernatant of cells producing the recombi-
nant 5F11 antibody (Rec) or tissue culture medium spiked with the 
5F11 monoclonal antibody purified from the parent hybridoma (Hyb). 
Staining of the recombinant 5F11 [Rec 5F11, (e)] is indistinguishable 
from that of the parent hybridoma [Hyb 5F11, (f)], red. Nuclei are coun-
terstained in blue (DAPI). Abbreviations: cns = central nervous system; 
e = eye; CMV = cytomegalovirus promoter; L = leader sequence; C = 
constant region; V = variable region.Crosnier et al. BMC Biology 2010, 8:76
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erate primers used to amplify the VL and VH are also likely
to introduce amino acid changes at the N-terminus of
each chain. The antibody isotype, if not originally an
IgG1, will be altered, and finally the antibodies produced
in HEK293E cells will contain different glycans. In order
to determine the consequences of these changes on the
antibody affinity, we compared each recombinant anti-
body to the original hybridoma supernatant using a BIA-
core instrument. Each antigen and a control were
immobilized at approximate molar equivalence on a sen-
sor chip; either the hydridoma or the recombinant anti-
body was injected until saturation had been achieved
(data not shown) and the rate of dissociation of the anti-
body was then followed for several hours. Of the four
recombinant antibodies tested, three (clones SI2-Unc5b,
SI3-Flrt3, and SI4-Jamc.2) were essentially indistinguish-
able from the original hybridoma demonstrating that the
changes due to the AscI site at the VH-CH1 junction, and
those due to the VL and VH-region degenerate primers, do
not affect antibody affinity, at least for these antibodies
(Figure 3b-d). In contrast, the affinity of the recombinant
SI5-Lrrn1 antibody was reduced >200-fold (Figure 3e).
Isotyping revealed that the original hybridoma antibody
was an IgM which would have more avid binding than the
dimeric IgG of the recombinant form. Eliminating IgM
isotype antibodies by screening with isotype-specific sec-
ondary antibodies could avoid this problem.
Recombinant antibodies have expected staining patterns 
on wholemount fixed tissue
In order to test our recombinant antibodies on wholem-
ount fixed tissue, we determined the embryonic expres-
sion patterns of the flrt3, unc5b and jamc.2 genes and
compared them to the antibody staining. At 24 hpf, flrt3
was expressed in a broad stripe at the mid-hindbrain
boundary (Figure 4a) and the recombinant anti-Flrt3
antibody (SI3-Flrt3) also showed cell surface localization
Table 2: A summary of the antibodies selected in this study.
Target Antigen Antibody name Clone VL VH Formalin sensitive?
Fusion 1 1.1 Jamc.1 1.1.1 V14-111+J2 ND ND
1.2 Unc5b SI1-Unc5b 1.2.1 V17-127+J4 V2-2+D1+J4 Y
SI2-Unc5b 1.2.2 V5-48+J5 V1-14+D1+J4 N
1.2.3 Cloning halted
1.3 Lrrc4a 1.3.1 Clone lost
1.4 Flrt3 SI3-Flrt3 1.4.1 V3-7+J1 V1-66+D2+J3 N
1.4.2 Cloning halted
1.5 Appa No positive clone
Fusion 2 2.1 Jamb.1 No positive clone
2.2 Jamc.1 No positive clone
2.3 Jamc.2 SI4-Jamc.2 2.3.1 V10-96+J1 V3-2+D2+J1 N
2.4 Vasn 2.4.1 N.D. V5-6+D2+J2 ND
2.5 Lrrn1 SI5-Lrrn1 2.5.1 V4-57+J5 V1-77+D3+J2 N
The pooled antigens used in the immunizations are numbered, and details of the V, D and J segments identified are listed for each antibody. 
Antibodies were numerically named with the SI prefix for Sanger Institute.
ND = not determinedCrosnier et al. BMC Biology 2010, 8:76
http://www.biomedcentral.com/1741-7007/8/76
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of the Flrt3 receptor in the same territory (Figure 4b, c).
Similarly, unc5b was expressed in the dorsal part of the
retina (Figure 4d) and this staining was recapitulated
using the recombinant anti-Unc5b (SI2-Unc5b) antibody
which showed cell surface staining in the dorsal retina
(Figure 4e, f). Neither the jamc.2  gene nor SI4-Jamc.2
antibody showed staining on zebrafish embryos at differ-
ent stages up to 48 hpf demonstrating that this gene was
not expressed during early embryogenesis.
Discussion
High quality, validated monoclonal antibodies are valu-
able biomedical reagents but their isolation can be time-
consuming, unpredictable and expensive. By immunizing
with pools of antigens and quickly cloning the produc-
tively rearranged variable antibody regions, we have
greatly reduced the time, number of animals, and
resources needed to isolate monoclonal antibodies that
work on fixed wholemount tissues. Importantly, this pro-
cedure is accessible to smaller laboratories since it does
not require expensive automated infrastructures or large
clone libraries.
Antibodies that work in immunohistochemistry proto-
cols are of most use for developmental and cell biologists
but the protocols used often have long wash steps and
therefore require high affinity antibodies. Here we have
shown that the recombinant antibodies produced can
have half-lives of many hours and are suitable for whole-
mount immunohistochemistry protocols. We have also
shown that amino acid changes introduced within the
variable regions by using degenerate primers to amplify
the rearranged heavy and light fragments do not signifi-
cantly affect the specificity or affinity of the recombinant
antibody. In contrast, we observed a large decrease in
binding avidity when the antibody isotype was changed
from an avid decameric IgM to a bivalent IgG1. In order
to avoid this problem, positive antibodies of the IgM iso-
type should be identified and eliminated at an early stage
of the screening process using isotype-specific secondary
antibodies.
Previous attempts to raise mouse monoclonal antibod-
ies to zebrafish cell surface blood cell differentiation
markers using fluorescence-activated cell sorting (FACS)-
sorted zebrafish cells met with little success, most likely Figure 3 Sensitivity to formalin treatment and affinity measure-
ment of recombinant antibodies. (a) Recombinant antibodies SI1-
Unc5b and SI2-Unc5b were tested for formalin fixation sensitivity by 
ELISA following antigen treatment with a 4% formalin solution. (b-e) 
The dissociation rates of the recombinant (red line) antibodies were 
compared to the original hybridoma antibodies (blue line) using sur-
face plasmon resonance. Antibodies are: (b) SI3-Flrt3, (c) SI4-Jamc.2, (d) 
SI2-Unc5b and (e) SI5-Lrrn1. In order to facilitate comparison, binding 
at saturation was normalized to 100% and rebinding was minimized by 
immobilizing low levels of target protein and washing at 37°C using 
high flow rates (100 μL/min).
Figure 4 Recombinant monoclonal antibodies recapitulate their 
gene expression patterns on wholemount fixed zebrafish embry-
os. (a-c) Dorsal views of a 24 hpf zebrafish embryo showing flrt3 gene 
expression by in situ hybridization on the midbrain side of the mid-
hindbrain boundary (a) and antibody staining with SI3-Flrt3 [green in 
(b), white in (c)]. (d-f) Lateral view of a dissected 24 hpf eye showing ex-
pression of the unc5b gene in the dorsal retina (d) and antibody stain-
ing with SI2-Unc5b [green in (e), white in (f)]. (b, e) red = DAPI nuclear 
stain. Scale bars = 50 μm.Crosnier et al. BMC Biology 2010, 8:76
http://www.biomedcentral.com/1741-7007/8/76
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due to the presence of highly immunogenic glycans that
were not protein-specific [20]. Zebrafish proteins
expressed in a human cell line contain glycans that are
not immunogenic in mice, making our recombinant pro-
tein library an ideal source of antigens for generating a
zebrafish antibody resource. Importantly, although we
have used this procedure to raise antibodies against cell
surface zebrafish proteins, it could, in principle, be used
to raise antibodies against any antigen that develops an
immune response in mice, including intracellular pro-
teins.
Recent technical advances could allow further refine-
ments of the method: specificity screening on protein
microarrays should permit to increase the number of
pooled antigens (possibly 50 or more) used for the immu-
nizations. Quicker immunization procedures such as the
Repetitive Immunization at Multiple Sites (RIMMS) [30]
in which antigens are administered over just an 11-day
period could also further reduce the time taken to select
antibodies. Methods for selecting monoclonal antibodies
from single antibody-secreting cells have been recently
developed but, crucially, do not enable collection of suffi-
cient reagent for specificity screening before single cell
RT-PCR amplification [31,32]. However, we have recently
established that cell culture time can be reduced further
by bypassing the 5-day expansion step before RT-PCR.
Cloning the productively rearranged light and heavy
chains of selected monoclonal antibodies into a single
mammalian expression vector facilitates their distribu-
tion and is an ideal format to build large reagent
resources. It is also a very flexible system since additional
properties such as purification tags (FLAG, poly-His) and
reporter proteins (alkaline phosphatase, horseradish per-
oxidase or fluorescent proteins) can be easily added at the
C-terminus of the heavy chain. Recent improvements in
mammalian expression systems can now rapidly yield
over 1 g/L of recombinant antibody from a transient
transfection [33], raising new hopes for the rapid and
large scale production of these valuable reagents.
Conclusions
We have reported here the development of a procedure
for cell and developmental biologists which streamlines
the production of monoclonal antibodies recognizing
a n ti ge ns  in w hole m ou n t  fix ed t is su e . I n t his  pa pe r ,  we
have used the method to raise antibodies against
zebrafish proteins but it could also be broadly applied to
any antigen that can raise a humoral immune response in
mice. As only minimal equipment is required, this tech-
nique can also be used by smaller laboratories. Cloning of
the rearranged light and heavy chains of selected mono-
clonal antibodies into a single mammalian expression
vector facilitates their distribution, making scope for the
creation of valuable antibody resources.
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